TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Antibiotic Prophylaxis in Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Undergoing colorectal surgery (incision, excision or anastomosis of the large bowel, including anastomosis of small to large bowel)~* Age \>18.~* Expected duration of surgery \> 2hours~* Creatinine clearance \> 40 ml/min~* Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens.~* Patient capable of giving informed consent~* Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery, urological surgery, gynaecological surgery.~* If it is not possible to obtain intra-operative blood samples e.g. difficult vascular access, or pre-operative swabs e.g. anatomy makes it difficult to obtain, patients will be included and this information treated as missing data. Patients on antibiotic treatment for an existing infection (except SSIs) can be included in the study~Exclusion Criteria:~* Unable to consent~* Pregnancy~* Expected duration of surgery \<2hours~* Creatinine clearance \<40ml/min~* Individual level microbiological advice for non cefuroxime based prophylaxis~* Cephalosporin allergy~* Penicillin allergy (hypersensitivity reaction only)~* Coumarin (warfarin and acenocoumarol) treatment~* Active blood borne virus infection e.g. HIV, hepatitis.~* Seizure history~* Concurrent use of probenecid~* Current participation in a research project aimed at reducing SSIs~* Antibiotics for treatment of a systemic Gram negative infection within 2 hours of initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin. Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic Gram negative antibiotics).~* A current diagnosis of a SSI at the time of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard regimen (Type: ACTIVE_COMPARATOR): Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
- Interventional regimen (Type: EXPERIMENTAL): Cefuroxime continuous infusion targeting 64mg/l serum concentrations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Myocardial infarction with evidence of significant myocardial necrosis defined as a rise in creatinine kinase \>800 U/l and a troponin T-level (or troponin I-level) \>10x upper limit of normal (ULN). In addition at least 1 of the following criteria must be the met:~   * Symptoms of ischemia~  * ECG (electrocardiogram) changes indicative of new ischemia (new ST-T changes or new LBBB)~  * Imaging evidence of new regional wall motion abnormality~2. 18 - 80 years of age~3. Informed consent has to be given in written form~4. estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73m2~5. Blood pressure before first drug dosing: Riva Rocci (RR) systolic \>110 mmHg~6. Blood pressure before first drug dosing: Riva Rocci (RR) diastolic \>70 mmHg~7. ≤72h after myocardial infarction (after the performance of a coronary angiography)~Exclusion Criteria:~1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis~2. Blood potential hydrogen (pH) \< 7,32~3. Known allergy to SGLT-2 inhibitors~4. Hemodynamic instability as defined by intravenous administration of catecholamine, calcium sensitizers or phosphodiesterase inhibitors~5. \>1 episode of severe hypoglycemia within the last 6 months and treatment with insulin or sulfonylurea~6. Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)~7. Acute symptomatic urinary tract infection (UTI) or genital infection~8. Patients currently being treated with any SGLT-2 inhibitor or having received treatment with any SGLT-2 inhibitor within the 4 weeks prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): The subjects will receive Empagliflozin 10mg.
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): The subjects will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cataracts (Grade 2-4 of Emery-Little Classification) with planned cataract removal by phacoemulsification in both eyes;~* Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;~* Calculated lens power within the available range;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Any pathology that could reduce visual potential;~* Hypotony or the presence of a corneal implant;~* Residual, recurrent, active ocular or eyelid disease;~* Poorly dilating pupil;~* Any contraindication to cataract;~* Eyes with two different levels of cataract grade;~* Pregnant, or planned pregnancy during the study;~* Expected to require an ocular surgical treatment at any time during the study;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLACS (Type: EXPERIMENTAL): Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
- Conventional (Type: ACTIVE_COMPARATOR): Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~2. At least 18 years of age~3. Otherwise in good health, as determined by physical exam and medical history~4. If female, and of child-bearing potential, is using an acceptable form of birth control~5. Negative urine pregnancy test at screening, if applicable~6. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~1. Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.~2. Subjects who had previous gastrointestinal surgeries.~3. Subjects with known or suspected electrolyte abnormalities such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.~4. Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.~5. Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~6. Subjects undergoing colonoscopy for foreign body removal and decompression.~7. Subjects who are pregnant or lactating, or intending to become pregnant during the study.~8. Subjects of childbearing potential who refuse a pregnancy test.~9. Subjects allergic to any preparation components~10. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.~11. Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polyethylene glycol 3350 based bowel preparation (Type: ACTIVE_COMPARATOR): Polyethylene glycol 3350 based bowel preparation
- BLI800 (Type: EXPERIMENTAL): BLI800

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Dysmenorrhea patients with a total dysmenorrhea score (sum of the two sub-scores: severity of dysmenorrhea and use of analgesics) of at least 3 points in each of the last two menstruations before randomization (baseline observation phase)~* Patients with dysmenorrheic pain during the 2 baseline cycles before randomization. Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with possible radiation towards back or thighs recorded in the Patient Diary in correspondence with a withdrawal and/or menstrual bleeding episode. Pain could start up to 2 days before the onset of the bleeding episode the bleeding and terminates on the last day of bleeding of before~* Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two menses before randomization (baseline observation phase)~* Willingness to use a barrier method (i.e., non-hormonal method) for contraception during the study. Acceptable methods of contraception include (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device.~Exclusion Criteria: - Patients who have organic diseases of which surgical treatment is prioritized by the investigator~* Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in size of the longest diameters~* Patients with ovarian chocolate cysts having solid part in the cyst~* Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EE20/DRSP(BAY86-5300)-flexibel extended regimen (Type: EXPERIMENTAL): One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
- EE20/DRSP(BAY86-5300)-28 days cyclic regimen (Type: ACTIVE_COMPARATOR): One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Follow-up Trial of Proglucamune® in the Treatment of Protective Qi Deficiency, a TCM Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or females aged 18 to 65 years (inclusive) without regard to race or ethnic background~2. Provide a signed Informed Consent prior to entry in the study.~3. Willing to follow all study instructions and consume the assigned investigational product for 12 weeks.~4. Not currently taking a beta-glucan containing supplement or any other supplement that might interfere with the study design.~5. Ability to swallow tablets and pills.~6. Exhibit an PQi Insufficiency score \> 2 (See Primary Outcome Measure)~Exclusion Criteria:~1. Persons diagnosed by TCM as having medical conditions other than low Qi.~2. Significant acute or chronic illness or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.~3. Scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all of the necessary study visits.~4. Persons medically diagnosed with depression or anxiety disorders.~5. Persons with a history of alcohol abuse or other substance abuse within the previous 2 years.~6. Females who are attempting to become pregnant, pregnant, lactating or who have given birth within 1 year.~7. Persons who have had a medical surgery in the past 4 weeks or have scheduled a surgery during the study period.~8. Persons currently enrolled in a clinical trial, or who have completed a clinical trial within the last 4 weeks.~9. Allergies to mushrooms or other fungi.~10. Significant problems with constipation or diarrhea.~11. A lifestyle or schedule incompatible with the study protocol.~12. Persons who are allergic to yeast products, have autoimmune disease/an immune disorder, or take antidepressants, blood thinners (anticoagulants, acetylsalicylic acid), or immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Proglucamune treatment (Type: EXPERIMENTAL): Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject receiving a primary, partial liver graft from a living donor~* subject must receive the first dose of tacrolimus and corticosteroids after operation and are expected to be maintained on tacrolimus throughout the study. MMF could be combined~Exclusion Criteria:~* subjects receiving a multi-organ transplant or having previously received an organ transplant (including liver re-transplantation)~* subjects receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used~* subjects allergic or intolerant to macrolide antibiotics or tacrolimus~* subjects requiring immunosuppressive treatment and / or systemic chemotherapy prior to transplantation~* subjects with malignancies or a history of malignancy within the last 5 years, with the exception of those with basalioma or squamous cell carcinoma of the skin~* subjects with systemic infection requiring treatment, except viral hepatitis~* subjects with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus~* subjects with serum creatinine \> 1.5mg/dl~* subjects taking or having taken potassium preserved diuretics~* subjects with any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator~* subjects participating or having participated in another clinical trial and/or those taking or having taken an investigational / non-registered drug in the past 28 days~* subjects or donors known to be HIV positive~* donors known to be HBV, HCV positive and/or IgM positive of CMV, EBV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Intravenous Prograf therapy followed by oral Advagraf therapy
- Arm 2 (Type: ACTIVE_COMPARATOR): Intravenous Prograf therapy followed by oral Prograf therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented porphyria cutanea tarda (PCT)~* Willing to give informed consent~* Age 18 or greater~Exclusion Criteria:~* Blistering skin lesions due to another condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Low-dose hydroxychloroquine 100 mg by mouth twice weekly
- Phlebotomy (Type: ACTIVE_COMPARATOR): Phlebotomy 450 mL biweekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥ 18 years~* Intubated for ≥ 36 hours~* Scheduled extubation~* Informed written consent~Exclusion Criteria:~* pregnancy~* history of postextubation laryngeal dyspnea~* laryngeal disease~* tracheotomy~* patient receiving corticotherapy prior to admission~* traumatic intubation~* participation to this study or to another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 80 years of age;~* Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification; of the acute arthritis of primary gout;~* At least 2 gout flares in the year prior to the screening visit;~* Serum uric acid greater than or equal to 7.5 mg/dL at the screening visit;~Exclusion Criteria:~* Acute gout flare within 2 weeks of the screening visit or during screening;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the screening visit;~* Previous exposure to Rilonacept;~* Use of allopurinol, benzbromarone, febuxostat, probenecid or sulfinpyrazone within 3 months prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
- Rilonacept 80 mg (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
- Rilonacept 160 mg (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female cigarette smokers, 18-75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt~* Smoked an average of at least 10 cigarettes per day during past year and over past month, and exhaled carbon monoxide (CO) \> 10 ppm at screening~* Current or past diagnosis of MDD without psychotic features, either single or recurrent, using DSM IV TR based on clinical assessment and confirmed by SCID and at least one of the following:~* On stable antidepressant treatment for MDD (stable dose for at least 2 months)~* Major depressive episode, using DSM IV TR, in the past 2 years successfully treated~Exclusion Criteria:~* Current or past diagnosis of dementia, schizophrenia, schizoaffective disorder, or other psychotic disorder, bipolar I disorder, bipolar II disorder.~* Subjects with antisocial, schizotypal, or any other personality disorder severe enough to compromise the subject's ability to comply with the study requirements..~* Current use of either bupropion or nortryptiline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- varenicline (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete